Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 8
Submit an article Journal homepage
88
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

Hans Tilman Steinmetza Outpatient Clinics for Hematology and Oncology, Cologne, GermanyCorrespondence[email protected]
View further author information
,
J. Toczek-Thiela Outpatient Clinics for Hematology and Oncology, Cologne, GermanyView further author information
,
J. Lipkeb Outpatient Clinics for Hematology and Oncology, Dortmund, GermanyView further author information
,
R. Lierschc Outpatient Clinics for Hematology and Oncology, Münster, GermanyView further author information
,
A. Sauerd Outpatient Clinics for Hematology and Oncology, Potsdam, GermanyView further author information
,
H. Tesche Outpatient Clinics for Hematology and Oncology, Frankfurt/Main, GermanyView further author information
,
J. Heßlingf Outpatient Clinics for Hematology and Oncology, Berlin, GermanyView further author information
,
U. Totzkeg TDS, Basel, SwitzerlandView further author information
&
S. Schmitza Outpatient Clinics for Hematology and Oncology, Cologne, GermanyView further author information
 show all
Pages 1476-1479 | Received 01 Mar 2023, Accepted 10 May 2023, Published online: 31 May 2023

References

  • Bewersdorf JP, Zeidan AM. Risk-adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Cancers. 2021;13(7):1610.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Moreno Berggren D, Folkvaljon Y, Engvall M, et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS Register. Br J Haematol. 2018;181(5):614–627.
  • Park S, Fenaux P, Greenberg P, et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol. 2016;174(5):730–747.
  • Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–3510.
  • Pereira A, Nomdedeu M, Aguilar JL, et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol. 2011;86(3):245–250.
  • Kaphan E, Laurin D, Lafeuillade B, et al. Impact of transfusion on survival in patients with myelodysplastic syndromes: current knowledge, new insights and transfusion clinical practice. Blood Rev. 2020;41:100649.
  • Rozema J, van Roon EN, Kibbelaar RE, et al. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: a population-based study. Transfusion. 2021;61(10):2877–2884.
  • Steinmetz HT, Germing U, Sauer A, et al. Myelodysplastic syndromes (MDS) in regular care in Germany–the oldest patients come to the fore. Leuk Lymphoma. 2018;59(5):1244–1247.
  • Garelius HK, Johnston WT, Smith AG, et al. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. J Intern Med. 2017;281(3):284–299.
  • Boyko O, Simonova M, Knysh N, et al. Erythropoietin as an independent prognostic factor in myelodysplastic syndromes. Exp Oncol. 2021;43:41–45.
  • Jayakar J, Wells RA, Khalaf D, et al. Validation of the Nordic Scoring System for erythropoietic stimulating agents in MDS using IWG 2006 Erythroid Response Criteria. Blood. 2012;120(21):1721.
  • Zeidan AM, Gore SD, McNally DL, et al. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013;119(21):3870–3878.
  • Zeidan AM, Zhu W, Stahl M, et al. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leuk Lymphoma. 2019;60(13):3181–3187.
  • Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39(1):48–56.
  • Giagounidis AA, Germing U, Wainscoat JS, et al. The 5q- syndrome. Hematology. 2004;9(4):271–277.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.